盐酸芬太尼(Fentanyl Hydrochloride) - 药物靶点：δ opioid receptor x κ opioid receptor x μ opioid receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Fentanyl hydrochloride (JAN)、Ionsys

靶点

δ opioid receptor x κ opioid receptor x μ opioid receptor

作用方式

激动剂

作用机制

δ opioid receptor激动剂(δ-阿片受体激动剂)、κ opioid receptor激动剂(κ-阿片受体激动剂)、μ opioid receptor激动剂(μ-阿片受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症-

非在研适应症

镇痛术后疼痛

原研机构

The Medicines Company (Spain) SL

在研机构-

非在研机构

ALZA Corp.Incline Therapeutics Europe Ltd.Janssen-Cilag International NV

+ [1]

最高研发阶段撤市

首次获批日期

欧盟 (2006-01-24),

术后疼痛

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H29ClN2O

InChIKeyLHCBOXPPRUIAQT-UHFFFAOYSA-N

CAS号1443-54-5

查看全部结构式(2)

关联

5

项与盐酸芬太尼相关的临床试验

ChiCTR2400081101

/ Suspended临床4期IIT

Effects of remimazolam combined with afentanyl hydrochloride on hemodynamics during anesthesia induction in children with congenital heart disease

开始日期2024-03-01

申办/合作机构

上海交通大学医学院附属上海儿童医学中心

NCT05553665

/ Not yet recruitingN/AIIT

Medical Thoracoscopy for Undiagnosed Transudative and Exudative Pleural Effusions

Indonesia is one of country that contributes the most cases of tuberculosis worldwide. Tuberculosis is the most commonly etiology of exudative pleural effusion. There have been many studies about undiagnosed exudative pleural effusions, but there are not many studies about the use of medical thoracoscopy for diagnosing transudative and exudative pleural effusion, especially on biomarkers of C-Reactive Protein (CRP), D-dimer, Adenosine Deaminase (ADA), Antinuclear Antibody (ANA), C3 C4 complements, Cancer Antigen 125 (CA-125), Xpert Mycobacterium Tuberculosis (Xpert MTB), Lupus Erythematosus cell (LE cell), cytology (effusion and smear) and histopathology. Information gained from those biomarkers via thoracocentesis and medical thoracoscopy, etiology of exudative and transudative pleural effusion can be detected earlier and clearly, especially etiology of infection, autoimmune, and malignancy that further can be used to reduce patients' hospitalization period, mortality, and to develop the new therapeutic agents.

开始日期2022-11-01

申办/合作机构

University of Indonesia

[+1]

NCT04679818

/ Completed临床3期IIT

Postoperative Consequences of Intraoperative NOL Titration

To demonstrate that intraoperative NOL-guided titration of fentanyl improves initial recovery characteristics.

开始日期2020-12-30

申办/合作机构

The Cleveland Clinic Foundation

100 项与盐酸芬太尼相关的临床结果

登录后查看更多信息

100 项与盐酸芬太尼相关的转化医学

登录后查看更多信息

100 项与盐酸芬太尼相关的专利（医药）

登录后查看更多信息

11,300

项与盐酸芬太尼相关的文献（医药）

2025-06-01·Analytical Science Advances

Development and Validation of a Gas Chromatography‐Mass Spectrometry Method for the Determination of Fentanyl and Butyryl Fentanyl in Oral Fluid

作者: Anzillotti, Luca ; Cecchi, Rossana ; Camedda, Nicola ; Dagoli, Sara

ABSTRACTSynthetic opioids are lab‐synthesized substances that target the brain's opioid receptors, offering analgesic and sedative effects. Amongst them, fentanyl is one of the most widely used to intervene in chronic pain in moderate to severe cancer situations. Butyryl fentanyl (BF) is a novel synthetic opioid whose use is growing. Its potency is seven times that of morphine and, unlike fentanyl, BF can only be obtained through illegal sources. Fentanyl and its analogues are related to harmful intoxications and an increase in opioid‐related mortality in many countries, such as in the United States and Europe in recent years. This work developed and validated an effective and sensitive method based on solid‐phase extraction followed by gas chromatography‐mass spectrometry (GC‐MS) for the determination of fentanyl and BF in oral fluid samples. To the best of our knowledge, it is the first successful attempt to quantify these analytes using GC‐MS with a limit of quantification (LOQ) of 1 ng/mL in OF. Intra‐day and inter‐day percentage coefficient of variation were found within 1%–3% and 1%–14%, respectively, while accuracy ranged from 92% to 102% at four concentration levels (lower LOQ [LLOQ], 3, 20, 40 ng/mL) in accordance with the established criteria. The absolute recovery values were in the range of 80.0%–100.0%. The method was linear for all analytes, with quadratic regression of calibration curves always higher than 0.99. The validated method demonstrated its great potential to detect and quantify fentanyl and its analogue in OF and it can be useful not only in forensic investigations of addiction histories but also in epidemiological studies on the spread of fentanyl and BF among workers and/or drivers.

2025-03-01·Talanta

Femtosecond laser-induced Au nanostructure-decorated with plasmonic nanomaterials for sensitive SERS-based detection of fentanyl

Article

作者: Chen, Hung-Wen ; Hsu, Ju-Yin ; Hsu, Yun-Tzu ; Liu, Keng-Ku ; Chen, Chien-Hung

Fentanyl and its analogs have emerged as the main factor behind the ongoing opioid abuse globally in recent years. However, the existing techniques for sensitive and accurate detection of fentanyl are often complex, laborious, expensive, and restricted to central healthcare facilities. We reported herein a plasmonic biochip fabricated by the femtosecond laser-induced nanostructures and plasmonic nanomaterials for sensitive SERS-based detection of fentanyl. Yolk-shell structured plasmonic nanomaterials are employed owing to their unique optical properties. The femtosecond laser direct writing technique creates three-dimensional silicon nanostructures followed by gold deposition and the immobilization of plasmonic nanomaterials. This SERS biochip fabricated by the femtosecond laser-induced nanostructure decorated with yolk-shell structured plasmonic nanomaterials enables the rapid and sensitive detection of fentanyl with the limit of detection of 3.33 ng/mL.

2025-03-01·Journal of Forensic Sciences

Prevalence of new psychoactive substances and drugs of abuse in the hair of individuals diagnosed with substance use disorder: Polydrug and emerging pattern of consumption

Article

作者: Pelletti, Guido ; Grech, Marialuisa ; Pascali, Jennifer Paola ; Pirani, Filippo ; Giorgetti, Arianna ; Barone, Rossella ; Mohamed, Susan ; Fais, Paolo

AbstractPeople diagnosed with substance use disorder (SUD) might represent a high‐risk subpopulation for New Psychoactive Drugs (NPS) consumption, and hair analysis offers a unique perspective to assess drug prevalence in this population. The present study aims to assess the prevalence of NPS and their co‐consumption with traditional drugs of abuse (DoA) in individuals diagnosed with SUD. Hair samples from patients under care at the addiction treatment service of Bologna, Italy, for a diagnosed SUD, were collected during 2023 and analyzed by ultra‐high‐performance liquid chromatography‐mass spectrometry (UHPLC–MS/MS), using a previously validated method. Among the 88 patients included, 95.5% tested positive for at least one substance, of which 88.1% for traditional DoA only, and 11.9% for NPS in addition to DoA. Among the positive samples, patients were found positive for more than two drugs in 67.9% of cases. The combination of DoA and NPS was more frequent in the younger age group (<21–30 years old, compared to 31–70, p = 0.025). Ketamine was detected in 8.0% of all samples, with mean hair levels 49.68 pg/mg (ranging 8.55–81.90 pg/mg) and was frequently accompanied by cocaine (85.7% of cases). Fentanyl was detected in 3.4% of all samples, while, among NPS, buphedrone was the only one detected. Our retrospective study highlights that the consumption of NPS is relatively low compared to other vulnerable or high‐risk populations. However, the prevalence of polydrug consumption and the high rate of ketamine–cocaine combination warrant careful monitoring even in this population.

100 项与盐酸芬太尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10811	盐酸芬太尼	N02AB03 N01AH01	DB00813

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
术后疼痛	药物发现	冰岛	Janssen-Cilag International NV	2006-01-24
术后疼痛	药物发现	挪威	Janssen-Cilag International NV	2006-01-24
术后疼痛	药物发现	列支敦士登	Janssen-Cilag International NV	2006-01-24
术后疼痛	药物发现	欧盟	Janssen-Cilag International NV	2006-01-24
镇痛	药物发现	-	ALZA Corp.	2004-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04679818 (CTgov)	临床3期	麻醉 \| 药物不良反应	72	PMD-200 Nol-guided opioid administration (PMD-200 NOL Group)	遞廠積艱憲夢繭簾壓夢(醖蓋觸繭醖鬱夢積製艱) = 築醖壓繭願選餘構糧衊簾積憲構憲憲廠構廠鏇 (齋願夢製廠築遞窪觸壓, 衊積鹹衊顧廠選糧繭膚 ~ 遞糧鏇壓餘鏇壓蓋蓋夢) 更多	-	2024-06-21
NCT04679818 (CTgov)	临床3期	麻醉 \| 药物不良反应	72	Routine opioid management (Control Group)	遞廠積艱憲夢繭簾壓夢(醖蓋觸繭醖鬱夢積製艱) = 遞製醖夢鏇艱窪蓋鹽範簾積憲構憲憲廠構廠鏇 (齋願夢製廠築遞窪觸壓, 範窪鏇淵鹹顧製獵膚構 ~ 齋觸餘繭餘醖齋遞獵夢) 更多	-	2024-06-21
Pubmed \| Yonsei Med J	N/A	镇痛	-	Fentanyl-based IV-PCA	(選鹹鹹製齋鑰鑰鑰製衊) = 鏇構夢鑰構築壓醖選觸艱製餘範範膚糧鹹憲鬱 (鏇蓋糧襯繭衊醖鹹積醖 )	-	2014-01-01